Eleven Therapeutics’ Post

🌟 Exciting Opportunity Alert! 🌟 Are you a passionate Nucleic Acid Chemist looking to make a real impact in the world of RNA therapeutics? Eleven Therapeutics is on the hunt for a talented Oligonucleotide Chemist to join our dynamic team in Cambridge, UK! 🧬💼 If you're ready to be part of a creative and innovative group that's transforming drug discovery with cutting-edge RNA biology, combinatorial chemistry, and A.I., this is the perfect role for you! 🤩✨ 🔍 What We're Looking For: - Expertise in solid phase synthesis (SPS) and automated ON synthesizers - Strong background in oligonucleotide chemistry - Collaborative spirit and a drive for excellence Join us in our mission to develop next-gen nucleic acid therapeutics and make a difference in patients' lives across the globe! 🌍❤️ Interested? Apply now or share with someone who would be a great fit! https://lnkd.in/d8e6HEfc #JobOpening #ChemistryJobs #RNAtherapeutics #JoinOurTeam #ElevenTx #CambridgeJobs

🦀 🦑 🐳 Excited to be at Biomed Israel 2024, the leading life sciences and health tech event! This week, 150 startups and industry leaders are gathering in Tel Aviv to explore innovations shaping healthcare. Join us Wednesday for a special session moderated by Dr. Iris Grossman, PhD and Dr. Boaz Hirshberg. They will focus on revolutions in cardio-metabolism. Iris, our CTxO responsible for pharmaceutical and business development at Eleven Therapeutics, says: “The existing drugs are excellent, but the industry strives to upgrade them in several ways: lowering the dose and frequency of injections, minimizing side effects, increasing weight loss, and targeting fat rather than muscle. This will make these treatments more effective long-term and improve patient compliance.” Discover how Israeli experts and startups are enhancing treatments for better patient outcomes. Read more: https://lnkd.in/dXMNmJAm #BiomedIsrael #HealthcareInnovation #CardioMetabolismRevolution 🚀🔬

🌟Thrilled to welcome Miri Shiradski to our Chemistry team as an Analytical Chemist 🌟 👩🔬 With valuable experience from the industry and a Master's degree from the University of Warwick, Miri brings with her a wealth of experience and expertise that will undoubtedly elevate our capabilities here at Eleven Therapeutics. Her proficiency in HPLCs, LCMSs, and other analytical techniques, coupled with her proactive approach to method development, will enhance our purification and QC efforts 💪 Welcome aboard, Miri! 🎉 #11TX #Biotech #Science #Welcome

🎙️ New Podcast Alert! Our very own CEO, Dr. Yaniv Erlich was recently featured on “Geekonomy”, one of the prominent podcasts in Israel, offering insights on groundbreaking advancements in genetic medicine, the fascinating world of slimming drugs and much more. Whether you're passionate about science, health, or simply curious about the latest innovations (and a Hebrew speaker), this podcast is for you. Tune in to stay ahead of the curve in the ever-evolving landscape of biotech and healthcare: https://lnkd.in/dD8rJ_nw #Biotechnology #Healthcare #Innovation #Podcast #11TX

💥 When Paloma Giangrande, our CTO, was asked by STAT what is her favorite lab equipment, she gave a brilliant answer! 📱 Read her interview now :) https://shorturl.at/ehmsG #biotech #11TX

👑 We’re thrilled to extend a warm welcome to André Filipe Dias Xavier, our newest addition to the Discovery Team in Cambridge, UK. Andre brings a wealth of experience, having spent six years in academic and industry settings after his Master's thesis at Aalborg University. His expertise includes molecular biology and clinical samples, which will support our drug development efforts.  We are confident that Andre’s diverse skill set and industry background will be invaluable to our team. Join us in welcoming André as we embark on new scientific endeavors at Eleven Therapeutics! 😎 🤖 #biotech #11TX

🚀 Exciting News at Eleven Therapeutics! 🚀 💙 Thrilled to announce Dr. Paloma Giangrande as our new Chief Technology Officer (CTO). A luminary in nucleic acid therapeutics, Dr. Giangrande brings over a decade of groundbreaking experience, including leadership roles at Moderna and Wave Life Sciences. As Editor-in-Chief at Molecular Therapy Nucleic Acids, her impact on the scientific community is exceptional.   In her role as CTO, Dr. Giangrande will drive the strategic direction of our xRNA technologies, propelling Eleven Therapeutics to new heights in nucleic acid therapeutics. Prof. Yaniv Erlich, CEO and Co-Founder, said: "So happy to welcome Dr. Paloma Giangrande. Her expertise and leadership will significantly boost our capabilities as we revolutionize mRNA therapeutics."   Officially taking the reins on January 2nd, 2024, Dr. Giangrande's appointment reinforces Eleven Therapeutics' commitment to transformative solutions in mRNA therapeutics. Read more: https://shorturl.at/grxDV Paloma Giangrande #ElevenTherapeutics #mRNA #Biotech #Innovation #11TX